A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia
- 18 May 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 24 (8) , 1059-1073
Abstract
Benign prostatic hyperplasia (BPH) is a common disease among men and significantly impacts quality of life by causing lower urinary tract symptoms (LUTS). Current medical therapies are not always adequate in controlling LUTS or slowing disease progression, and there is unmet need for new effective therapeutic options. The authors review the standard current medical therapies for BPH which include the use of α-1 blockers, 5-α reductase inhibitors, combination therapy and PDE inhibitors. Following this, the authors then discuss new therapies that are currently undergoing preclinical and clinical investigation. Existing preclinical and clinical trials have highlighted many promising therapies to treat BPH. Further investigation with larger clinical trials is needed to establish these drugs as standard therapies. As the number of drugs in the arsenal against BPH continues to grow, providers and patients will have to engage in a discussion that weighs the risks and benefits of each therapy.Keywords
This publication has 88 references indexed in Scilit:
- Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic reviewBJU International, 2012
- Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract SymptomsJAMA, 2011
- The potential for NX-1207 in benign prostatic hyperplasia: an update for cliniciansTherapeutic Advances in Chronic Disease, 2011
- Effects of 100 and 300 Units of Onabotulinum Toxin A on Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Phase II Randomized Clinical TrialJournal of Urology, 2011
- Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasiaTherapeutics and Clinical Risk Management, 2011
- Phase 1 and 2 Studies Demonstrate the Safety and Efficacy of Intraprostatic Injection of PRX302 for the Targeted Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaEuropean Urology, 2011
- Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and societyWorld Journal of Urology, 2010
- Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPHWorld Journal of Urology, 2009
- Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling ApproachCancer Prevention Research, 2008
- The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence SocietyNeurourology and Urodynamics, 2002